Inhibrx Biosciences, Inc.

NASDAQ:INBX

Biotechnology

Healthcare
$69.06 -2.74%

-$2.58 today

Market cap
$1.02B
Beta
3.32
P/E (TTM)
-11.0
EPS (TTM)
-$8.35
52W Low $13.97High $155.29

Volume 0.29M

Average 0.43M

INBX Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Inhibrx Biosciences, Inc.NASDAQ: INBX

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense remains negative

Q1 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $2K. Over 3 fiscal years it compounded at -12.6% a year.

Context

  • Income tax expense amounted to 0.2% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Income tax expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $500.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$2K+0.0% YoY
LTMMar 2026
$2K+0.0% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+0.0%——
3-year CAGR-12.6%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
2K USD
Year-over-year change
+0.0%
4-year CAGR
+0.0%

Income Tax Expense vs competitors

How INBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +0.0% is the 2nd highest of 4, against a peer median of -23.1%.
  • Income tax expense amounts to 0.2% of revenue for INBX, versus a peer median of 0.5%.
INBX Competitors
Income Tax Expense for INBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TECXTectonic Therapeutic, Inc.LTM Mar 2026$1.23M USD———
GENBGenerate Biomedicines, Inc.FY2025$163K USD-23.1%—0.5%
ABSIAbsci CorporationLTM Mar 2026$91K USD+68.5%—5.0%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$2K USD+0.0%-12.6%0.2%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$0 USD——0.0%
JANXJanux Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
IMTXImmatics N.V.LTM Mar 2026-€942K EUR-124.8%—2.5%
Peer median (excluding INBX) —-23.1%—0.5%

Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.13M2.19M1.8M200K1.3M
Cost of Revenue2.69M110.19M1.19M2.29M2.48M
Gross Profit4.44M(107.99M)609K(2.09M)(1.18M)
Gross Margin62.3%-4926.7%33.8%-1042.5%-91.0%
Research & Development71.44M110.19M190.65M203.74M113.03M
Selling, General & Admin12.36M21.12M29.38M127.91M23.3M
Operating Expenses12.34M21.12M219.83M329.36M133.84M
Depreciation & Amortization1.2M1.23M1.19M2.29M2.48M
EBITDA(75.37M)(125.82M)(206.69M)1.7B(132.54M)
EBITDA Margin-1057.8%-5739.8%-11482.9%851675.0%-10195.5%
Operating Income(76.56M)(129.12M)(219.22M)(331.45M)(135.03M)
Operating Margin-1074.6%-5890.4%-12178.9%-165724.0%-10386.5%
Interest Income5.22M16.11M11.92M10.94M7.55M
Interest Expense5.22M16.11M31.84M13.49M12.2M
Other Income / Expenses(5.2M)(16.11M)(20.5M)2.02B(5.03M)
Income Before Tax(81.77M)(145.22M)(239.72M)1.69B(140.05M)
Pre-Tax Margin-1147.6%-6625.1%-13318.0%843787.0%-10773.3%
Income Tax Expense2K3K3K2K2K
Net Income(81.77M)(145.23M)(241.36M)1.69B(140.06M)
Net Margin-1147.6%-6625.3%-13408.9%843786.0%-10773.5%
EPS (Basic)(2.15)(3.62)(5.12)116.58(9.04)
EPS (Diluted)(2.15)(3.62)(5.12)116.58(9.04)
Weighted Avg Shares38.01M40.11M47.13M14.48M15.49M
Weighted Avg Shares (Diluted)38.01M40.11M47.13M14.48M15.49M

Inhibrx Biosciences, Inc.

NASDAQ:INBX

Intrinsic Alpha fair value

Locked

Current Price

$69.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.